GB201603568D0 - Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer - Google Patents

Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer

Info

Publication number
GB201603568D0
GB201603568D0 GBGB1603568.5A GB201603568A GB201603568D0 GB 201603568 D0 GB201603568 D0 GB 201603568D0 GB 201603568 A GB201603568 A GB 201603568A GB 201603568 D0 GB201603568 D0 GB 201603568D0
Authority
GB
United Kingdom
Prior art keywords
peptide
combination
bladder cancer
cell based
urinary bladder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1603568.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1603568.5A priority Critical patent/GB201603568D0/en
Publication of GB201603568D0 publication Critical patent/GB201603568D0/en
Priority to MX2018010167A priority patent/MX2018010167A/es
Priority to CR20180398A priority patent/CR20180398A/es
Priority to SG10202008107QA priority patent/SG10202008107QA/en
Priority to IL261266A priority patent/IL261266B2/en
Priority to PCT/EP2017/054559 priority patent/WO2017148888A1/en
Priority to CR20210035A priority patent/CR20210035A/es
Priority to AU2017227967A priority patent/AU2017227967B2/en
Priority to CR20210033A priority patent/CR20210033A/es
Priority to MA043690A priority patent/MA43690A/fr
Priority to SG10202110228Y priority patent/SG10202110228YA/en
Priority to MA43090A priority patent/MA43090A1/fr
Priority to BR112018016734A priority patent/BR112018016734A2/pt
Priority to EA201891670A priority patent/EA201891670A1/ru
Priority to CN201780014493.6A priority patent/CN109152825A/zh
Priority to CR20210034A priority patent/CR20210034A/es
Priority to SG11201806951TA priority patent/SG11201806951TA/en
Priority to JP2018543337A priority patent/JP2019516663A/ja
Priority to US15/445,461 priority patent/US10400011B2/en
Priority to KR1020187027578A priority patent/KR20180118702A/ko
Priority to CN202211593287.4A priority patent/CN116375797A/zh
Priority to IL302705A priority patent/IL302705A/en
Priority to CA3014848A priority patent/CA3014848A1/en
Priority to EP21171324.3A priority patent/EP3915577A1/en
Priority to MA054832A priority patent/MA54832A/fr
Priority to EP17707843.3A priority patent/EP3423085A1/en
Priority to TW106106638A priority patent/TWI641617B/zh
Priority to PH12018501723A priority patent/PH12018501723A1/en
Priority to CL2018002360A priority patent/CL2018002360A1/es
Priority to CONC2018/0008763A priority patent/CO2018008763A2/es
Priority to ZA2018/05838A priority patent/ZA201805838B/en
Priority to US16/457,012 priority patent/US20190330274A1/en
Priority to US16/671,994 priority patent/US20200055899A1/en
Priority to US16/671,981 priority patent/US11673917B2/en
Priority to CL2020001565A priority patent/CL2020001565A1/es
Priority to CL2020001563A priority patent/CL2020001563A1/es
Priority to US16/915,354 priority patent/US11180532B2/en
Priority to CL2021000177A priority patent/CL2021000177A1/es
Priority to JP2021086571A priority patent/JP7201740B2/ja
Priority to US17/333,945 priority patent/US12103984B2/en
Priority to US17/339,157 priority patent/US12084522B2/en
Priority to AU2021204201A priority patent/AU2021204201B2/en
Priority to US17/832,246 priority patent/US20220363717A1/en
Priority to JP2022206084A priority patent/JP7564183B2/ja
Priority to CL2023001324A priority patent/CL2023001324A1/es
Priority to US18/345,700 priority patent/US20240083947A1/en
Priority to AU2023204323A priority patent/AU2023204323A1/en
Priority to JP2024167901A priority patent/JP2025011134A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/836—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
GBGB1603568.5A 2016-03-01 2016-03-01 Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer Ceased GB201603568D0 (en)

Priority Applications (48)

Application Number Priority Date Filing Date Title
GBGB1603568.5A GB201603568D0 (en) 2016-03-01 2016-03-01 Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
MX2018010167A MX2018010167A (es) 2016-03-01 2017-02-28 Peptidos, combinaciones de peptidos y medicamentos basados en celulas para el uso en la inmunoterapia contra el cancer de vejiga y otros tipos de cancer.
CR20180398A CR20180398A (es) 2016-03-01 2017-02-28 Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga y otros tipos de cáncer
SG10202008107QA SG10202008107QA (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
IL261266A IL261266B2 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
PCT/EP2017/054559 WO2017148888A1 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CR20210035A CR20210035A (es) 2016-03-01 2017-02-28 PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y CÉLULAS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE VEJIGA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0398)
AU2017227967A AU2017227967B2 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CR20210033A CR20210033A (es) 2016-03-01 2017-02-28 PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y CÉLULAS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE VEJIGA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0398)
MA043690A MA43690A (fr) 2016-03-01 2017-02-28 Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
SG10202110228Y SG10202110228YA (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
MA43090A MA43090A1 (fr) 2016-03-01 2017-02-28 Peptides, combinaisons de peptides et médicaments basés sur les cellules pour l'immunothérapie contre le cancer de la vessie urinaire et d'autres cancers
BR112018016734A BR112018016734A2 (pt) 2016-03-01 2017-02-28 peptídeos, combinações de peptí¬deos e medicamentos baseados em células para uso na imunoterapia contra o câncer de bexiga e outros cânceres
EA201891670A EA201891670A1 (ru) 2016-03-01 2017-02-28 Пептиды, комбинации пептидов и медикаменты на клеточной основе для применения в иммунотерапии рака мочевого пузыря и других видов рака
CN201780014493.6A CN109152825A (zh) 2016-03-01 2017-02-28 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
CR20210034A CR20210034A (es) 2016-03-01 2017-02-28 PÉPTIDOS, COMBINACIONES DE PÉPTIDOS Y CÉLULAS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE VEJIGA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0398)
SG11201806951TA SG11201806951TA (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
JP2018543337A JP2019516663A (ja) 2016-03-01 2017-02-28 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤
US15/445,461 US10400011B2 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
KR1020187027578A KR20180118702A (ko) 2016-03-01 2017-02-28 방광암 및 기타 암들에 대한 면역요법에서의 사용을 위한 펩티드, 펩티드의 조합 및 세포 기반 약제들
CN202211593287.4A CN116375797A (zh) 2016-03-01 2017-02-28 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
IL302705A IL302705A (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CA3014848A CA3014848A1 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
EP21171324.3A EP3915577A1 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
MA054832A MA54832A (fr) 2016-03-01 2017-02-28 Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
EP17707843.3A EP3423085A1 (en) 2016-03-01 2017-02-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
TW106106638A TWI641617B (zh) 2016-03-01 2017-03-01 用於膀胱癌和其它癌症免疫治療的肽、肽組合物和基於細胞的藥物
PH12018501723A PH12018501723A1 (en) 2016-03-01 2018-08-15 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CL2018002360A CL2018002360A1 (es) 2016-03-01 2018-08-17 Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer
CONC2018/0008763A CO2018008763A2 (es) 2016-03-01 2018-08-22 Péptidos, combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer
ZA2018/05838A ZA201805838B (en) 2016-03-01 2018-08-30 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
US16/457,012 US20190330274A1 (en) 2016-03-01 2019-06-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
US16/671,994 US20200055899A1 (en) 2016-03-01 2019-11-01 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
US16/671,981 US11673917B2 (en) 2016-03-01 2019-11-01 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CL2020001565A CL2020001565A1 (es) 2016-03-01 2020-06-11 Péptidos (seq id no. 119, seq id no. 2 a seq id no. 63, seq id no. 65 a seq id no. 118, y seq id no. 120 a seq id no. 149), combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer. (divisional solicitud 201802360)
CL2020001563A CL2020001563A1 (es) 2016-03-01 2020-06-11 Péptidos (seq id no. 64, seq id no. 2 a seq id no. 63, seq id no. 65 a seq id no. 118, y seq id no. 120 a seq id no. 149), combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer. (divisional solicitud 201802360)
US16/915,354 US11180532B2 (en) 2016-03-01 2020-06-29 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
CL2021000177A CL2021000177A1 (es) 2016-03-01 2021-01-22 Péptidos, combinaciones de péptidos, células y kits para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201802360)
JP2021086571A JP7201740B2 (ja) 2016-03-01 2021-05-23 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤
US17/333,945 US12103984B2 (en) 2016-03-01 2021-05-28 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
US17/339,157 US12084522B2 (en) 2016-03-01 2021-06-04 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
AU2021204201A AU2021204201B2 (en) 2016-03-01 2021-06-22 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
US17/832,246 US20220363717A1 (en) 2016-03-01 2022-06-03 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
JP2022206084A JP7564183B2 (ja) 2016-03-01 2022-12-22 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤
CL2023001324A CL2023001324A1 (es) 2016-03-01 2023-05-08 Péptidos, combinaciones, células para inmunoterapia contra cáncer de vejiga y otros cánceres
US18/345,700 US20240083947A1 (en) 2016-03-01 2023-06-30 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
AU2023204323A AU2023204323A1 (en) 2016-03-01 2023-07-05 Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
JP2024167901A JP2025011134A (ja) 2016-03-01 2024-09-26 膀胱がんおよびその他のがんに対する免疫療法で使用するためのペプチド、ペプチド組み合わせ、および細胞ベースの薬剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1603568.5A GB201603568D0 (en) 2016-03-01 2016-03-01 Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer

Publications (1)

Publication Number Publication Date
GB201603568D0 true GB201603568D0 (en) 2016-04-13

Family

ID=55807140

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1603568.5A Ceased GB201603568D0 (en) 2016-03-01 2016-03-01 Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer

Country Status (18)

Country Link
US (1) US10400011B2 (enExample)
EP (2) EP3423085A1 (enExample)
JP (2) JP2019516663A (enExample)
KR (1) KR20180118702A (enExample)
CN (1) CN109152825A (enExample)
AU (2) AU2017227967B2 (enExample)
BR (1) BR112018016734A2 (enExample)
CA (1) CA3014848A1 (enExample)
CO (1) CO2018008763A2 (enExample)
CR (4) CR20180398A (enExample)
EA (1) EA201891670A1 (enExample)
GB (1) GB201603568D0 (enExample)
IL (1) IL261266B2 (enExample)
MA (2) MA43090A1 (enExample)
MX (1) MX2018010167A (enExample)
SG (3) SG10202110228YA (enExample)
TW (1) TWI641617B (enExample)
WO (1) WO2017148888A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
AU2017386682A1 (en) 2016-12-28 2019-07-25 Invvax, Inc. Influenza vaccines
CA3058807A1 (en) 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Protein antigens and uses thereof
LT3652215T (lt) 2017-07-14 2021-05-25 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
CA3083242A1 (en) * 2017-11-21 2019-05-31 Naofumi MIWA Human cancer cell metastasis inhibitory agent and human cancer cell determination agent
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN111684062A (zh) 2018-02-09 2020-09-18 伊玛提克斯美国公司 制造t细胞的方法
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
WO2019204683A1 (en) 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
TW202015719A (zh) 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
CN113538407B (zh) 2018-12-29 2022-10-14 北京市商汤科技开发有限公司 锚点确定方法及装置、电子设备和存储介质
WO2020191172A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
ES2991645T3 (es) 2019-06-06 2024-12-04 Immatics Biotechnologies Gmbh Clasificación con contraselección mediante péptidos de secuencia similar
EP3982980A4 (en) * 2019-06-12 2023-11-29 BioNTech US Inc. NEOANTIGEN COMPOSITIONS AND USES THEREOF
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN111118011B (zh) * 2020-02-11 2022-09-06 昆明医科大学 一种抑制hsa_circ_0027478表达的siRNA及其应用
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CN115975943A (zh) * 2020-07-14 2023-04-18 广州泛恩生物科技有限公司 基于acp5阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
MX2023012899A (es) 2021-05-05 2023-11-08 Immatics Biotechnologies Gmbh Polipeptidos de union a antigeno bma031 mejorados.
WO2023025851A1 (en) 2021-08-24 2023-03-02 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
US12319720B2 (en) * 2021-08-31 2025-06-03 Washington University Neoantigen vaccines for triple negative breast cancer
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
EP4514834A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
EP4514821A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
AU2023262596A1 (en) 2022-04-28 2024-12-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023215825A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN115785206B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标07及其用途
CN115961032A (zh) * 2022-09-19 2023-04-14 深圳市罗湖区人民医院 一种膀胱癌相关突变基因的检测探针、检测试剂盒、突变质控品
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025021968A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Antigen binding proteins against mageb2
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2444691A1 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2003104429A2 (en) 2002-06-10 2003-12-18 Idec Pharmaceuticals Corporation Genes overexpressed by ovarian cancer and their use in developing novel therapeutics
ES2341802T3 (es) * 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
KR100906145B1 (ko) * 2006-05-30 2009-07-03 한국생명공학연구원 Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제
EP2402437B1 (en) * 2006-07-05 2016-06-01 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
DK2172211T3 (en) * 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
TW201124530A (en) * 2009-12-01 2011-07-16 Oncotherapy Science Inc IMP-3 oligopeptides and vaccines including the same
EP2336771A1 (en) * 2009-12-16 2011-06-22 Universität Duisburg-Essen HAS3v2 as tumor marker
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201511792D0 (en) * 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers

Also Published As

Publication number Publication date
WO2017148888A1 (en) 2017-09-08
KR20180118702A (ko) 2018-10-31
SG11201806951TA (en) 2018-09-27
MX2018010167A (es) 2018-11-29
US10400011B2 (en) 2019-09-03
CN109152825A (zh) 2019-01-04
EP3915577A1 (en) 2021-12-01
JP2021129580A (ja) 2021-09-09
MA43690A (fr) 2021-06-02
CR20210033A (es) 2021-02-10
IL261266B1 (en) 2023-06-01
CR20210035A (es) 2021-02-10
IL261266B2 (en) 2023-10-01
SG10202110228YA (en) 2021-10-28
CA3014848A1 (en) 2017-09-08
MA43090A1 (fr) 2018-10-31
AU2017227967A1 (en) 2018-09-06
AU2021204201A1 (en) 2021-07-15
SG10202008107QA (en) 2020-09-29
CR20210034A (es) 2021-02-10
TWI641617B (zh) 2018-11-21
TW201734039A (zh) 2017-10-01
AU2017227967B2 (en) 2021-03-25
EP3423085A1 (en) 2019-01-09
EA201891670A1 (ru) 2019-02-28
AU2021204201B2 (en) 2023-04-13
JP7201740B2 (ja) 2023-01-10
IL261266A (en) 2018-10-31
BR112018016734A2 (pt) 2018-12-26
JP2019516663A (ja) 2019-06-20
US20170253633A1 (en) 2017-09-07
CR20180398A (es) 2018-11-30
CO2018008763A2 (es) 2018-08-31

Similar Documents

Publication Publication Date Title
GB201603568D0 (en) Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
SG10202003124TA (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
ZA201800513B (en) Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
ZA201801036B (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
LT3430027T (lt) Peptidas, skirtas panaudoti imunoterapijoje prieš nesmulkialąstelinį plaučių vėžį ir smulkialąstelinį plaučių vėžį
SG10202001485UA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
SG10202005950XA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
IL269741A (en) Peptides and combination thereof for use in the immunotherapy against cancers
ZA201704726B (en) Peptides and their use in the treatment of skin
IL254228A0 (en) Cell therapy agent for cancer treatment and combined therapy with it
IL258609A (en) New peptides and a combination of peptides for use in immunotherapy against several types of cancer
ZA201805838B (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
SG11202111476RA (en) Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
IL257707A (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and against other types of cancer
PL3700546T3 (pl) Peptydy wnt5a do zmniejszania liczby nowotworowych komórek macierzystych
GB201810635D0 (en) Peptides and cancer treatment
ZA202001435B (en) Abx196 for use in the treatment of bladder cancer
EP3648789C0 (en) MTMR2-S POLYPEPTIDE FOR USE IN THE TREATMENT OF MYOPATHY
SG10202110335PA (en) Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
HK40000492A (en) Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers
SG11201802955VA (en) Peptides of use in the preventive and curative treatment of alopecia

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)